Switching to Tresiba is Cost-effective in a Real-world Setting
A new analysis of real-world data on November 7, 2017, stated that switching to Tresiba (insulin degludec) for treatment of type 1 and type 2 diabetes is highly cost-effective.
Tresibais an insulin degludec, an ultralong-acting basal insulin analogue developed by Novo Nordisk. It is administered via subcutaneous injection once daily to control the blood sugar level by providing duration of action beyond 42 hours with stable glucose-lowering effect. Tresibaallows flexibility in dosing time with a minimum eight hours between injections, if administration in same time of day is not possible.
The analysis was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress. This new analysis was based on an Italian subpopulation of the EUropean TREsiba AudiT (EU-TREAT) study, a European multicenter, real-world evidence study, where 2,550 people suffering from type 1 and type 2 diabetes were involved in investigating the effect of switching to Tresiba from another basal insulin. Key benefits associated with switching to Tresiba include reductions in hypoglycaemia and the use of health system resources in a calculation based on a treatment period of one year.
“In addition to the body of evidence supporting its benefits in clinical practice, Tresiba has been shown to be a cost-effective treatment option across various European healthcare systems. We hope these encouraging findings from real-world clinical practice will help make Tresiba available to even more people living with type 1 and type 2 diabetes around the world.” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk
Cost-effectiveness was evaluated on the basis of change in hypoglycaemia rates, basal and prandial insulin dose, and body weight at six months after switching to Tresiba in 397 people with type 1 and 153 people with type 2 diabetes from Italy. These data build on previously reported real-world evidence which found that switching to Tresiba from other basal insulin, mainly insulin glargine U100 and insulin detemir, provides significant reductions in blood glucose levels with low rates of severe hypoglycaemic episodes by 92% in people with type 2 diabetes and by 85% in people with type 1 diabetes.
You may be interested
Ambulatory Services Market to Develop Rapidly by 2018 – 2026Albert R - August 19, 2018
Ambulatory Services Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share,…
Refurbished Medical Equipment Market Positive long-term growth outlook 2018-2026Albert R - August 19, 2018
Refurbished Medical Equipment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…
Stem Cell Assay Market Trends Estimates High Demand by 2026Albert R - August 19, 2018
Stem Cell Assay Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…